Kiromic Biopharma is an immuno-oncology, target discovery, and gene editing company developing highly effective and safe tumor-specific cancer engineered immunotherapies to face and defeat multiple cancer types. They are focused on extending the benefits of immunotherapy by leveraging DIAMOND AI (Kiromic Diamond Artificial Intelligence), which is a multi-purpose computational platform that can identify new cancer immunological targets for T-Cells and B-Cells.

Biotechnology

Kiromic Biopharma

Maurizio Chiriva-Internati

Lucia Piccotti

Sarah Madonna

Raquel Dien

Diane Duyen Nguyen

Brian Hungerford

Leonardo Mirandola

Trish Faulkner

Alan Guerrero

Scott Dahlbeck

The Scientific Advisory team at Kiromic Biopharma provides expert guidance on scientific and clinical strategies to advance the company's immuno-oncology research and development. They leverage their specialized knowledge to assess and refine the DIAMOND AI platform, ensuring the identification of new cancer immunological targets is both accurate and optimized for therapeutic use.

Scientific Advisory

Scientific Research and Operations

Leadership Team

��

Scientific Advisory

About

Team members

Other teams at Kiromic Biopharma

Scientific Research and Operations

Leadership Team

��������

Scientific Advisory

About

Team members

Other teams at Kiromic Biopharma

Scientific Research and Operations

Leadership Team

��